Clinical trials: Neoadjuvant Radiotherapy
Oral Cancer
A Study of Neoadjuvant Bio-C/T Followed by Concurrent Bio-R/T in High-risk Locally Advanced Oral Squamous Cell Carcinoma
Surgical resection followed by concurrent chemoradiotherapy is considered as the standard of care for locally advanced OSCC (LAOSCC).
- Trial name
- NCT00933387
- Testing
- Cetuximab,Paclitaxel,Cisplatin
- Where
- Taiwan
- Volunteers
- 47 people
- Sponsor
- National Health Research Institutes, Taiwan
Rectal Cancer
A Trial of High Intensity Versus Low Intensity Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
Neoadjuvant chemoradiotherapy (CRT) has been the standard therapy for local advanced rectal cancer. Pathological complete response (pCR) is an important prognostic factor for local control and survival.
- Trial name
- NCT01064999
- Testing
- Oxaliplatin, Capecitabine, Radiotherapy
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Fudan University
Glioblastoma
Preoperative Chemoradiation for Glioblastoma
Trial to determine the safety of neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
- Trial name
- NCT02092038
- Testing
- Temozolomide, partial brain irradiation, stereotactic biopsy of brain tumor
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tampa General Hospital
Rectal Cancer
Rectal Cancer And Pre-operative Induction Therapy Followed by Dedicated Operation. The RAPIDO Trial
Currently the 3-year disease free survival of patients with locally advanced rectal cancer is about 50%. Current standard treatment for patients at high risk of failing locally and/or systemically includes pre-operative long…
- Trial name
- RAPIDO (NCT01558921)
- Testing
- M1 scheme, standard long course chemoradiotherapy
- Where
- 56 sites in United States, Denmark and 5 more
- Volunteers
- 920 people
- Sponsor
- University Medical Center Groningen
Esophageal Neoplasms, Esophageal Diseases
Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of radiation therapy combined with anti-PD-1 antibody SHR-1210 followed by surgery in treating patients with resectable esophageal squamous cell carcinoma
- Trial name
- NCT03200691
- Testing
- 3-DCRT or IMRT radiation, anti-PD-1 antibody SHR-1210
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Hangzhou Cancer Hospital
Rectal Cancer
Leucine Plus Radiochemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Colorectal cancer (CRC), a prevalent gastrointestinal malignancy, is experiencing a rising incidence in China. Rectal cancer constitutes nearly half of all new CRC cases, with over half of these patients diagnosed at a locally…
- Trial name
- NCT07359989
- Testing
- Oral administration of Leucine
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Retroperitoneal Sarcoma, Liposarcoma
A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas
This phase I trial tests the safety, side effects, and best dose of abemaciclib and how well it works with radiation therapy before surgery in treating patients with high-risk adipocytic retroperitoneal sarcoma.
- Conditions
- Retroperitoneal Sarcoma, Liposarcoma, Dedifferentiated Liposarcoma
- Trial name
- NCT06025747
- Testing
- Abemaciclib, Computed Tomography, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Washington
Rectal Cancer
Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer
Despite treatment of locally advanced rectal cancer relapses are frequent. Several attempts to improve these results with therapy intensification have shown modest effect on disease free survival (DFS) and overall survival (OS).
- Trial name
- RECAP (NCT02910843)
- Testing
- Regorafenib, Capecitabine, Radiotherapy
- Where
- 7 sites in Switzerland
- Volunteers
- 25 people
- Sponsor
- Swiss Cancer Institute
Colorectal Cancer
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00081224
- Testing
- capecitabine, celecoxib, radiation therapy
- Volunteers
- 3 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
Response-adapted Postoperative Radiotherapy In Locally Advanced Head and Neck Cancer
This was a phase II clinical study. Patients with histologically confirmed, resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) without distant metastasis were enrolled.
- Trial name
- NCT07780877
- Testing
- Standard adjuvant radiotherapy based on pathologic findings, De-escalated radiotherapy with a reduced dose, De-escalated radiotherapy with omission of ENI
- Where
- 2 sites in China
- Volunteers
- 85 people
- Sponsor
- Fudan University
Rectal Cancer
IMMUNOlogical Microenvironment in REctal Adenocarcinoma Treatment.
Background The current management on rectal cancer based on TNM staging has some limitations. In locally advanced rectal cancer after neoadjuvant therapy the persistence of a complete response to therapy cannot be accurately…
- Trial name
- IMMUNOREACT2 (NCT04917263)
- Testing
- Immunohistochemistry, Flow citometry, Trascriptome analysis
- Where
- Italy
- Volunteers
- 544 people
- Sponsor
- University of Padova
Prostate Cancer
Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Hormones can stimulate the growth of prostate cancer cells. Hormone therapy may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00005044
- Testing
- Casodex, Eulexin, LHRH agonist
- Where
- 261 sites in United States, Canada
- Volunteers
- 1,579 people
- Sponsor
- Radiation Therapy Oncology Group
Rectal Tumors, Rectal Cancer
Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy
For advanced rectal tumors, the standard of care is neoadjuvant radiotherapy (RT) +/- chemotherapy followed by surgery 8-10 weeks later.
- Conditions
- Rectal Tumors, Rectal Cancer, Advanced Cancer
- Trial name
- NCT03258541
- Testing
- TraceIT®, Volumetric Arc Therapy (VMAT), Surgery
- Where
- Switzerland
- Volunteers
- 2 people
- Sponsor
- Thomas Zilli
Pancreatic Cancer
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an effective immune response to kill pancreatic cancer cells.
- Trial name
- NCT00727441
- Testing
- GVAX pancreatic cancer vaccine, cyclophosphamide
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladder in patients with muscle invasive bladder cancer.
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT07061964
- Testing
- Biospecimen Collection, Computed Tomography, Cystoscopy
- Where
- 182 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Towards Cure Via Only Ultra-short ICB in CSCC
The goal of this clinical trial is to determine whether cutaneous squamous cell carcinoma patients can be cured using only immunotherapy, without surgery or radiotherapy.
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Cutaneous Squamous Cell Carcinoma
- Trial name
- MATISSE 2 (NCT06823479)
- Testing
- Nivolumab, Ipilumimab
- Where
- 5 sites in Netherlands
- Volunteers
- 41 people
- Sponsor
- The Netherlands Cancer Institute
Low Anterior Resection Syndrome, Radiotherapy
Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)
Bowel dysfunction is common after a restorative rectal cancer resection. Neoadjuvant radiotherapy is an influential factor that impairs bowel function and quality of life.
- Conditions
- Low Anterior Resection Syndrome, Radiotherapy, Rectal Cancer
- Trial name
- PORTLARS (NCT05129215)
- Testing
- Questionnaire
- Where
- China
- Volunteers
- 901 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC
This study includes patients with resectable esophageal squamous cell carcinoma who will undergo local radiotherapy (PTV: 1.5Gy Bid, for 5 days), followed by neoadjuvant treatment with Serplulimab combined with cisplatin and…
- Trial name
- NCT07403435
- Testing
- Serplulimab
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Oral Squamous Cell Carcinoma (OSCC)
A Prospective Single-Arm Study（NCLDR）
To investigate the safety and efficacy of low-dose radiotherapy combined with chemotherapy and immunotherapy as neoadjuvant therapy for locally advanced oral squamous cell carcinoma (OSCC), and to explore whether low-dose…
- Trial name
- NCLDR (NCT07028918)
- Testing
- Low dose radiotherapy regimen, New adjuvant immunotherapy regimen, Surgical treatment
- Volunteers
- 35 people
- Sponsor
- Qilu Hospital of Shandong University
Soft Tissue Sarcoma
Neoadjuvant and Adjuvant Chemotherapy in High-risk Soft Tissue Sarcoma
Neo- and adjuvant chemotherapy is used in high-risk soft tissue sarcoma to improve systemic control. Patients in this trial are treated with 4 cycles of chemotherapy (EIA, etoposide, ifosfamide, adriamycin) preoperatively…
- Trial name
- NeoWTS (NCT01382030)
- Testing
- EIA chemotherapy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Heidelberg University